Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?

Reprod Biomed Online. 2004 Nov;9(5):505-10. doi: 10.1016/s1472-6483(10)61634-3.

Abstract

This study aimed to evaluate plasminogen activator inhibitor-1 (PAI-1) activity in PCOS. Thirty women with PCOS - 15 normal-weight and 15 obese - and 30 healthy women matched as a group for age and body mass index (BMI) were recruited. The homeostasis model assessment (HOMA) score was significantly elevated in obese compared with normal-weight women, in both PCOS women and controls. HOMA score was significantly higher in both PCOS groups relative to controls. After further adjustment for BMI, PAI-1 activity (IU/ml +/- SD) was significantly higher in the PCOS groups compared with controls. A significant positive correlation was found between HOMA score and BMI in PCOS and control groups. Serum PAI-1 activity was significantly related to BMI and HOMA score. When considering two BMI subgroups, there was no significant difference in the relationship between serum PAI-1 activity and HOMA score in both the control and PCOS groups. No other significant relationship was found between serum PAI-1 activity and any other hormonal or metabolic parameter. In conclusion, women with PCOS have significantly elevated PAI-1 activity independent of obesity, and it is speculated that elevated PAI-1 activity may be a factor in the increased cardiovascular morbidity seen in PCOS.

MeSH terms

  • Adolescent
  • Adult
  • Body Mass Index
  • Body Weight
  • Cardiovascular Diseases / blood*
  • Cardiovascular Diseases / mortality*
  • Female
  • Humans
  • Insulin Resistance
  • Obesity / blood
  • Obesity / mortality
  • Plasminogen Activator Inhibitor 1 / blood*
  • Polycystic Ovary Syndrome / blood*
  • Polycystic Ovary Syndrome / mortality*
  • Risk Factors

Substances

  • Plasminogen Activator Inhibitor 1